Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism

Free Radical Biology and Medicine

Volumn 49, Issue 2, 2010, Pages 301-305

  Fong, Pete ^a   Stafforini, Diana M ^b   Brown, Nancy J ^a   Pretorius, Mias ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Blood flow; Bradykinin; Isoprostanes; Nitric oxide; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; BRADYKININ; DILTIAZEM; ISOPROSTANE DERIVATIVE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME INHIBITION; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERTENSION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION;

ADULT; BRADYKININ; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; ENDOTHELIUM, VASCULAR; F2-ISOPROSTANES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; OXIDATIVE STRESS; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 77953543513     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.04.023     Document Type: Article

References (29)

1. Kharbanda R.K., Deanfield J.E. Functions of the healthy endothelium. Coron. Artery Dis. 2001, 12:485-491.
2. Robinson S.D., Ludlam C.A., Boon N.A., Newby D.E. Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1651-1656.
3. Newby D.E., McLeod A.L., Uren N.G., Flint L., Ludlam C.A., Webb D.J., Fox K.A., Boon N.A. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001, 103:1936-1941.
4. Lavi S., Yang E.H., Prasad A., Mathew V., Barsness G.W., Rihal C.S., Lerman L.O., Lerman A. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 2008, 51:127-133.
5. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 2005, 25:279-286.
6. Mehrabi M.R., Ekmekcioglu C., Tatzber F., Oguogho A., Ullrich R., Morgan A., Tamaddon F., Grimm M., Glogar H.D., Sinzinger H. The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc. Res. 1999, 43:492-499.
7. Quyyumi A.A., Ozkor M. Vasodilation by hyperpolarization: beyond NO. Hypertension 2006, 48:1023-1025.
8. Sametz W., Hummer K., Butter M., Wintersteiger R., Juan H. Formation of 8-iso-PGF(2alpha) and thromboxane A(2) by stimulation with several activators of phospholipase A(2) in the isolated human umbilical vein. Br. J. Pharmacol. 2000, 131:145-151.
9. Rajasekaran M., Hellstrom W.J., Sikka S.C. Nitric oxide induces oxidative stress and mediates cytotoxicity to human cavernosal cells in culture. J. Androl. 2001, 22:34-39.
10. Jourdan K.B., Mitchell J.A., Evans T.W. Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. Biochem. Biophys. Res. Commun. 1997, 233:668-672.
11. Hokanson D.E., Sumner D.S., Strandness D.E. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans. Biomed. Eng. 1975, 22:25-29.
12. Milne G.L., Sanchez S.C., Musiek E.S., Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2007, 2:221-226.
13. Stafforini D.M., McIntyre T.M., Prescott S.M. Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol. 1990, 187:344-357.
14. Cai H., Griendling K.K., Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharm. Sci. 2003, 24:471-478.
15. Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
16. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87:840-844.
17. Tang M., Cyrus T., Yao Y., Vocun L., Pratico D. Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 2005, 112:2867-2874.
18. De Caterina R., Cipollone F., Filardo F.P., Zimarino M., Bernini W., Lazzerini G., Bucciarelli T., Falco A., Marchesani P., Muraro R., Mezzetti A., Ciabattoni G. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 2002, 106:2543-2549.
19. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
20. Widlansky M.E. Shear stress and flow-mediated dilation: all shear responses are not created equally. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H31-H32.
21. De Keulenaer G.W., Chappell D.C., Ishizaka N., Nerem R.M., Alexander R.W., Griendling K.K. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ. Res. 1998, 82:1094-1101.
22. Grobe A.C., Wells S.M., Benavidez E., Oishi P., Azakie A., Fineman J.R., Black S.M. Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 290:L1069-L1077.
23. Silacci P., Desgeorges A., Mazzolai L., Chambaz C., Hayoz D. Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 2001, 38:1162-1166.
24. Ward N.C., Hodgson J.M., Puddey I.B., Mori T.A., Beilin L.J., Croft K.D. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic. Biol. Med. 2004, 36:226-232.
25. Cracowski J.L., Baguet J.P., Ormezzano O., Bessard J., Stanke-Labesque F., Bessard G., Mallion J.M. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003, 41:286-288.
26. Ghiadoni L., Magagna A., Versari D., Kardasz I., Huang Y., Taddei S., Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003, 41:1281-1286.
27. Cockcroft J.R., Chowienczyk P.J., Benjamin N., Ritter J.M. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N. Engl. J. Med. 1994, 330:1036-1040.
28. Panza J.A., Garcia C.E., Kilcoyne C.M., Quyyumi A.A., Cannon R.O. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995, 91:1732-1738.
29. Taddei S., Virdis A., Ghiadoni L., Magagna A., Favilla S., Pompella A., Salvetti A. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001, 37:943-948.